Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis.

Quan W, Fazlin Zulkifli H, Saari N, Shueb RH, Mustaffa N

Open source

DOI
10.3389/fphar.2025.1502931
Published
2025
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2025.1502931,
  title = {Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis.},
  author = {Quan W and Fazlin Zulkifli H and Saari N and Shueb RH and Mustaffa N},
  year = {2025},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2025.1502931},
  url = {https://doi.org/10.3389/fphar.2025.1502931}
}

RIS

TY  - JOUR
TI  - Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis.
AU  - Quan W
AU  - Fazlin Zulkifli H
AU  - Saari N
AU  - Shueb RH
AU  - Mustaffa N
PY  - 2025
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2025.1502931
UR  - https://doi.org/10.3389/fphar.2025.1502931
ER  - 

APA

W, Q., H, F. Z., N, S., RH, S., & N, M. (2025). Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2025.1502931

Source records